Corvus Pharmaceuticals, Inc. — Director's Dealing 2017

Jan 4, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2017-01-03

Reporting Person: CLARK IAN T (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-01-03	Stock Option (Right to Buy)	$14.43	A	30000	Acquired	2027-01-03	Common Stock (30000)	Direct

Footnotes

F1: The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from January 3, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.